Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9089562rdf:typepubmed:Citationlld:pubmed
pubmed-article:9089562lifeskim:mentionsumls-concept:C0043210lld:lifeskim
pubmed-article:9089562lifeskim:mentionsumls-concept:C0007226lld:lifeskim
pubmed-article:9089562lifeskim:mentionsumls-concept:C0035648lld:lifeskim
pubmed-article:9089562lifeskim:mentionsumls-concept:C0014912lld:lifeskim
pubmed-article:9089562lifeskim:mentionsumls-concept:C0013340lld:lifeskim
pubmed-article:9089562lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:9089562lifeskim:mentionsumls-concept:C0232970lld:lifeskim
pubmed-article:9089562lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:9089562lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:9089562lifeskim:mentionsumls-concept:C0591491lld:lifeskim
pubmed-article:9089562pubmed:issue2lld:pubmed
pubmed-article:9089562pubmed:dateCreated1997-6-10lld:pubmed
pubmed-article:9089562pubmed:abstractTextTo assess the effects of Femoston (2 mg micronised 17 beta oestradiol daily, sequentially combined in one tablet with 10 mg dydrogesterone for 14 days per 28 day cycle) on the serum lipid profile of postmenopausal women.lld:pubmed
pubmed-article:9089562pubmed:languageenglld:pubmed
pubmed-article:9089562pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9089562pubmed:citationSubsetIMlld:pubmed
pubmed-article:9089562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9089562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9089562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9089562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9089562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9089562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9089562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9089562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9089562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9089562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9089562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9089562pubmed:statusMEDLINElld:pubmed
pubmed-article:9089562pubmed:monthMarlld:pubmed
pubmed-article:9089562pubmed:issn0378-5122lld:pubmed
pubmed-article:9089562pubmed:authorpubmed-author:GelfandMMlld:pubmed
pubmed-article:9089562pubmed:authorpubmed-author:FugèrePPlld:pubmed
pubmed-article:9089562pubmed:authorpubmed-author:BissonnetteFFlld:pubmed
pubmed-article:9089562pubmed:issnTypePrintlld:pubmed
pubmed-article:9089562pubmed:volume26lld:pubmed
pubmed-article:9089562pubmed:ownerNLMlld:pubmed
pubmed-article:9089562pubmed:authorsCompleteYlld:pubmed
pubmed-article:9089562pubmed:pagination125-32lld:pubmed
pubmed-article:9089562pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:meshHeadingpubmed-meshheading:9089562-...lld:pubmed
pubmed-article:9089562pubmed:year1997lld:pubmed
pubmed-article:9089562pubmed:articleTitleCardiovascular risk factors during sequentially combined 17 beta oestradiol and dydrogesterone (Femoston); results from a one-year study in postmenopausal women.lld:pubmed
pubmed-article:9089562pubmed:affiliationJewish General Hospital, Montréal, Quebec, Canada.lld:pubmed
pubmed-article:9089562pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9089562pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:9089562pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:9089562pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:9089562pubmed:publicationTypeMulticenter Studylld:pubmed